Clopidogrel Bisulfate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	2-4 mg/kg	q24h	Duration: Long-term, often lifelong depending on underlying condition Notes: For IMHA, use 2-3 mg/kg q24h. For PLN, 2-4 mg/kg q24h. Administer with food to reduce GI upset. Monitor for bleeding.
Cat	PO	18.75 mg/cat (approximately 3-5 mg/kg)	q24h	Duration: Long-term, often lifelong for HCM or after ATE Notes: Commonly used as a quarter of a 75 mg tablet. Administer with food. Monitor for bleeding and bruising.
Horse	PO	2-4 mg/kg	q24h	Duration: Variable, depending on condition Notes: Limited studies; use with caution. May require higher doses due to variable absorption. Monitor for bleeding.
Cattle	PO	Not established	Not established	Duration: Not established Notes: Not commonly used; no approved dosage. Use only under veterinary supervision with careful monitoring.
Small Ruminants	PO	Not established	Not established	Duration: Not established Notes: Not commonly used; no approved dosage. Use only under veterinary supervision with careful monitoring.
Rabbit	PO	Not established	Not established	Duration: Not established Notes: Not commonly used; no approved dosage. Use only under veterinary supervision with careful monitoring.
Bird/Poultry	PO	Not established	Not established	Duration: Not established Notes: Not commonly used; no approved dosage. Use only under veterinary supervision with careful monitoring.

Clinical Indications & Species Uses

General Indications

Prevention of arterial thromboembolism in small animals
Reduction of platelet aggregation in hypercoagulable states

Dog (Canine)

Prevention of thromboembolism in dogs with immune-mediated hemolytic anemia (IMHA)
Reduction of risk of arterial thrombosis in dogs with protein-losing nephropathy (PLN)
Adjunctive therapy in dogs with pulmonary thromboembolism
Prevention of thrombus formation in dogs with heart disease (e.g., dilated cardiomyopathy) at risk of thromboembolism

Cat (Feline)

Prevention of arterial thromboembolism (ATE) in cats with hypertrophic cardiomyopathy (HCM)
Reduction of risk of recurrent ATE in cats with previous thromboembolic events
Adjunctive therapy in cats with aortic thromboembolism

Horse (Equine)

Prevention of thrombotic events in horses with laminitis or sepsis-associated coagulopathy
Adjunctive therapy in horses with jugular vein thrombosis
Reduction of platelet aggregation in horses with hypercoagulable states

Pharmacology & Mechanism of Action

Drug Class: Antiplatelet Agent | Pharmacological Group: Thienopyridine P2Y12 receptor antagonist

Mechanism of Action: Clopidogrel is a prodrug that requires hepatic biotransformation via cytochrome P450 enzymes (primarily CYP2C19 in humans, but in animals the specific isozymes may vary) to form an active thiol metabolite. This active metabolite irreversibly binds to the platelet P2Y12 subtype of ADP receptors, thereby preventing ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, which is the final common pathway for platelet aggregation. This inhibition is irreversible for the lifespan of the platelet (approximately 7-10 days in dogs, 3-5 days in cats, and 5-7 days in horses).

Pharmacodynamics: Clopidogrel inhibits platelet aggregation induced by ADP, but not by arachidonic acid or thrombin. It prolongs bleeding time and reduces platelet thrombus formation. The antiplatelet effect is dose-dependent and can be measured by platelet aggregometry or thromboelastography (TEG) with platelet mapping. In cats, clopidogrel has been shown to reduce platelet aggregation and is used to prevent arterial thromboembolism. In dogs, it is used to reduce the risk of thrombotic events, particularly in those with immune-mediated hemolytic anemia or protein-losing nephropathy.

⚡ Pharmacokinetics Summary

Absorption: Clopidogrel is well absorbed after oral administration, but the bioavailability of the active metabolite is low due to extensive first-pass metabolism. In dogs, oral bioavailability of the parent compound is approximately 30-50%, but the active metabolite exposure is variable. In cats, absorption is rapid, with peak plasma concentrations of the parent compound occurring within 1-2 hours.

Distribution: Clopidogrel and its active metabolite are highly protein-bound (approximately 94-98% in humans). The volume of distribution is large, indicating extensive tissue distribution. It crosses the placenta and is distributed into milk in lactating animals.

Metabolism: Clopidogrel is extensively metabolized in the liver. It is hydrolyzed by esterases to an inactive carboxylic acid derivative (85% of the dose), and the remaining 15% is metabolized by CYP450 enzymes to the active thiol metabolite. In dogs, CYP2B11 and CYP3A12 are involved; in cats, CYP1A1/2 and CYP3A are likely involved. There is significant inter-individual variability in metabolism, which may affect clinical response.

Excretion: The metabolites are excreted in urine (50%) and feces (46%). The elimination half-life of the active metabolite is short (approximately 7-8 hours in humans), but the antiplatelet effect persists for the life of the platelet. In dogs, the half-life of the parent compound is approximately 1-2 hours, but the active metabolite's effect lasts for several days.

Half-Life: Dogs: 1-2 hours (parent compound); Cats: 2-4 hours (parent compound); Horses: 1-2 hours (parent compound); Humans: 7-8 hours (active metabolite).

Bioavailability: Oral bioavailability of parent compound: Dogs ~30-50%, Cats ~50-70%, Horses ~30-40%. Active metabolite exposure is highly variable.

Protein Binding: 94-98% (parent compound and active metabolite) in humans; similar in dogs and cats.

Available Formulations & Strengths

Oral Tablet 75 mg, 300 mg (PO)

Oral Tablet (film-coated) 75 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
Hypersensitivity to clopidogrel or any component of the formulation
Severe hepatic impairment (due to reduced metabolism)
Concurrent use of other anticoagulants or antiplatelet agents (e.g., warfarin, aspirin) unless specifically indicated and monitored
Use in animals with bleeding disorders (e.g., von Willebrand disease, thrombocytopenia)

Warnings & Clinical Precautions:

Use with caution in animals with increased risk of bleeding (e.g., recent surgery, trauma, or gastrointestinal ulceration).
Discontinue 5-7 days before elective surgery to allow platelet function to recover.
Monitor for signs of bleeding (e.g., petechiae, ecchymoses, melena, hematuria).
In cats, use with caution in those with renal or hepatic impairment; dose adjustment may be necessary.
In horses, absorption may be erratic; consider monitoring platelet function if available.
Do not crush tablets; administer whole or split as directed.
Use with caution in pregnant or lactating animals; safety not established.
May cause gastrointestinal upset; administer with food to minimize.
In animals with a history of gastrointestinal ulceration, consider gastroprotectants.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, anorexia)
Increased bleeding time
Bruising or petechiae
Lethargy

Serious / Severe:

Hemorrhage (gastrointestinal, intracranial, or internal)
Thrombotic thrombocytopenic purpura (rare in humans, not reported in animals)
Aplastic anemia (rare)
Hepatic dysfunction (rare)

Rare:

Allergic reactions (rash, urticaria, angioedema)
Agranulocytosis
Stevens-Johnson syndrome (in humans, not reported in animals)
Interstitial pneumonitis

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Aspirin	Additive antiplatelet effects, increased risk of bleeding. In cats, combination may be used but with careful monitoring.	High
Warfarin and other anticoagulants (e.g., heparin, enoxaparin)	Increased risk of bleeding due to additive anticoagulant effects.	High
NSAIDs (e.g., carprofen, meloxicam)	Increased risk of gastrointestinal ulceration and bleeding due to additive antiplatelet and GI irritant effects.	Moderate
Omeprazole and other proton pump inhibitors (PPIs)	May reduce the antiplatelet effect of clopidogrel by inhibiting CYP2C19 (in humans; in animals, the interaction is less clear but possible).	Moderate
Fluoxetine and other SSRIs	May increase bleeding risk due to platelet inhibition.	Moderate
Ketoconazole and other CYP3A4 inhibitors	May alter metabolism of clopidogrel, potentially reducing activation or increasing toxicity.	Moderate
Rifampin and other CYP inducers	May increase metabolism of clopidogrel, potentially altering its efficacy.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Prolonged bleeding time
Spontaneous bleeding (epistaxis, melena, hematuria)
Petechiae and ecchymoses
Vomiting and diarrhea
Lethargy and weakness

Emergency Treatment Protocol: There is no specific antidote for clopidogrel overdose. Treatment is supportive and symptomatic. Discontinue the drug immediately. Administer fresh whole blood or platelet-rich plasma to restore platelet function if severe bleeding occurs. Consider the use of desmopressin (DDAVP) to improve platelet adhesion, though its efficacy is variable. Monitor vital signs and hematocrit. In severe cases, consider activated charcoal if ingestion was recent (within 1-2 hours) and the animal is stable. Provide gastrointestinal protectants (e.g., sucralfate) if GI bleeding occurs. Supportive care with IV fluids and blood pressure management may be necessary.

Food Animal Withdrawal Times

Clopidogrel is not approved for use in food animals in the United States. Extra-label use in food animals is prohibited under AMDUCA if an approved animal drug exists that is labeled for the indication and species. Therefore, withdrawal times have not been established. If used off-label in food animals, a prolonged withdrawal period (e.g., 30 days for meat and 7 days for milk) is recommended, but this is not based on official data. Consult with a veterinary pharmacologist for specific guidance.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from moisture. Keep in original container with desiccant. Do not repackage into non-light-resistant containers unless specified.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Plavix).

Extra-Label (Off-Label) Use: In the United States, clopidogrel is not FDA-approved for veterinary use. Its use in animals is extra-label (off-label) and must comply with the Animal Medicinal Drug Use Clarification Act (AMDUCA). Extra-label use is permitted only by or on the order of a licensed veterinarian within a valid veterinarian-client-patient relationship. It is prohibited to use clopidogrel in food animals if an approved animal drug exists for the same indication and species. For companion animals, extra-label use is common and accepted.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Clopidogrel is an important antiplatelet agent in veterinary medicine, particularly for cats with hypertrophic cardiomyopathy at risk of arterial thromboembolism. In dogs, it is used for immune-mediated hemolytic anemia and protein-losing nephropathy. The drug requires hepatic activation, and there is significant individual variability in response; therefore, monitoring platelet function (e.g., aggregometry, TEG with platelet mapping) may be beneficial in high-risk patients. In cats, the dose is often a quarter of a 75 mg tablet (18.75 mg) given once daily. In dogs, the dose is 2-4 mg/kg once daily. Adverse effects are primarily bleeding-related, and caution is needed with concurrent anticoagulants or NSAIDs. For food animals, use is discouraged due to lack of withdrawal data. Always educate owners on signs of bleeding and the importance of consistent administration. Store tablets in a dry place and do not crush them.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)